Global Pharmaceutical Partnering Terms and Agreements 2012-2018: Deal trends, players and financials

Date: May 1, 2018
Pages: 1000
Price:
US$ 2,995.00
License [?]:
Publisher: CurrentPartnering
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: GA9FB443B92EN
Leaflet:

Download PDF Leaflet

Global Pharmaceutical Partnering Terms and Agreements 2012-2018: Deal trends, players and financials
SUMMARY

Global Pharmaceutical Partnering Terms and Agreements 2012 to 2018 report provides a detailed understanding and analysis of how and why companies enter Pharmaceutical partnering deals

DESCRIPTION

Global Pharmaceutical Partnering Terms and Agreements 2012 to 2018 report provides a detailed understanding and analysis of how and why companies enter Pharmaceutical partnering deals.

This report provides details of the latest Pharmaceutical agreements announced in the life sciences since 2012.

The report takes the reader through a comprehensive review Pharmaceutical deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Pharmaceutical partnering deals.

The report presents financial deal term values for Pharmaceutical deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the Pharmaceutical partnering field; both the leading deal values and most active Pharmaceutical dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 8,000 online deal records of actual Pharmaceutical deals, as disclosed by the deal parties, are included towards the end of the report in a directory format – by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of Pharmaceutical dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Pharmaceutical dealmaking since 2012, including details of headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Pharmaceutical deals since 2012. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 most active companies in Pharmaceutical dealmaking with a brief summary followed by a comprehensive listing of Pharmaceutical deals announded by that company, as well as contract documents, where available.

Chapter 5 provides a comprehensive and detailed review of Pharmaceutical partnering deals signed and announced since Jan 2012, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of Pharmaceutical partnering deals signed and announced since Jan 2012. The chapter is organized by specific technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

A comprehensive series of appendices is provided organized by Pharmaceutical partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Pharmaceutical partnering and dealmaking since 2012.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Pharmaceutical technologies and products.

Key benefits

Global Pharmaceutical Partnering 2012-2018: Deal trends, players, financials and forecasts provides the reader with the following key benefits:

In-depth understanding of Pharmaceutical deal trends since 2012
Access to headline, upfront, milestone and royalty data
Analysis of the structure of Pharmaceutical agreements with real life case studies
Detailed access to actual Pharmaceutical contracts entered into by leading biopharma companies
Identify most active Pharmaceutical dealmakers since 2012
Insight into terms included in a Pharmaceutical partnering agreement, with real world examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

Global Pharmaceutical Partnering 2012-2018: Deal trends, players, financials and forecasts is intended to provide the reader with an in-depth understanding and access to Pharmaceutical trends and structure of deals entered into by leading companies worldwide.

Pharmaceutical Partnering Terms and Agreements includes:

Trends in Pharmaceutical dealmaking in the biopharma industry since 2012
Analysis of Pharmaceutical deal structure
Access to headline, upfront, milestone and royalty data
Case studies of real-life Pharmaceutical deals
Access to Pharmaceutical contract documents
Leading Pharmaceutical deals by value since 2012
Most active Pharmaceutical dealmakers since 2012

In Global Pharmaceutical Partnering 2012-2018: Deal trends, players, financials and forecasts, the available deals are listed by:

Company A-Z
Headline value
Stage of development at signing
Deal component type
Specific therapy target
Technology type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Pharmaceutical Partnering 2012-2018: Deal trends, players, financials and forecasts report provides comprehensive access to available deals and contract documents for over 8,000 Pharmaceutical deals.

Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How aresalesand payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

BENEFITS

Global Pharmaceutical Partnering 2012-2018: Deal trends, players, financials and forecasts provides the reader with the following key benefits:
  • In-depth understanding of Pharmaceutical deal trends since 2012
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of Pharmaceutical agreements with real life case studies
  • Detailed access to actual Pharmaceutical contracts entered into by leading biopharma companies
  • Identify most active Pharmaceutical dealmakers since 2012
  • Insight into terms included in a Pharmaceutical partnering agreement, with real world examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies
EXECUTIVE SUMMARY

CHAPTER 1 – INTRODUCTION

CHAPTER 2 – TRENDS IN PHARMACEUTICAL DEALMAKING

2.1. Introduction
2.2. Pharmaceutical partnering over the years
2.3. Most active Pharmaceutical dealmakers
2.4. Pharmaceutical partnering by deal type
2.5. Pharmaceutical partnering by therapy area
2.6. Pharmaceutical partnering by technology type
2.7. Deal terms for Pharmaceutical partnering
  2.7.1 Pharmaceutical partnering headline values
  2.7.2 Pharmaceutical deal upfront payments
  2.7.3 Pharmaceutical deal milestone payments
  2.7.4 Pharmaceutical royalty rates

CHAPTER 3 – LEADING PHARMACEUTICAL DEALS

3.1. Introduction
3.2. Top Pharmaceutical deals by value

CHAPTER 4 – MOST ACTIVE PHARMACEUTICAL DEALMAKERS

4.1. Introduction
4.2. Most active Pharmaceutical dealmakers
4.3. Most active Pharmaceutical partnering company profiles

CHAPTER 5 – PHARMACEUTICAL CONTRACTS DEALMAKING DIRECTORY

5.1. Introduction
5.2. Pharmaceutical contracts dealmaking directory

CHAPTER 6 – PHARMACEUTICAL DEALMAKING BY TECHNOLOGY TYPE

CHAPTER 7 – PARTNERING RESOURCE CENTER

7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking

APPENDICES

Appendix 1 – Pharmaceutical deals by company A-Z
Appendix 2 – Pharmaceutical deals by stage of development
Appendix 3 – Pharmaceutical deals by deal type
Appendix 4 – Pharmaceutical deals by therapy area
Appendix 5 – Deal type definitions

ABOUT WILDWOOD VENTURES

Current Partnering
Current Agreements
Recent report titles from Current Partnering

TABLE OF FIGURES

Figure 1: Pharmaceutical partnering since 2012
Figure 2: Active Pharmaceutical dealmaking activity since 2012
Figure 3: Pharmaceutical partnering by deal type since 2012
Figure 4: Pharmaceutical partnering by disease type since 2012
Figure 5: Pharmaceutical partnering by technology type since 2012
Figure 6: Pharmaceutical deals with a headline value
Figure 7: Pharmaceutical deals with an upfront value
Figure 8: Pharmaceutical deals with a milestone value
Figure 9: Pharmaceutical deals with a royalty rate value
Figure 10: Top Pharmaceutical deals by value since 2012
Figure 11: Most active Pharmaceutical dealmakers since 2012
Figure 12: Online partnering resources
Figure 13: Forthcoming partnering events
Skip to top


Ask Your Question

Global Pharmaceutical Partnering Terms and Agreements 2012-2018: Deal trends, players and financials
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: